Joincare Pharmaceutical Group Industry (600380) Fundamentals 2026 — P/E 14.8x, Revenue Analysis | SniperIQ
Joincare Pharmaceutical Group Industry (600380) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥19.2B, trading at ¥10.48 on the SHH. This SniperIQ fundamentals page covers Joincare Pharmaceutical Group Industry's valuation (P/E 14.8x, P/B 1.2x), profitability (net margin 8.9%), revenue (¥15.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Joincare Pharmaceutical Group Industry's market cap?
Joincare Pharmaceutical Group Industry (600380) has a market capitalization of approximately ¥19.2B, trading at ¥10.48 on the SHH. Market cap moves with the live share price.
What is Joincare Pharmaceutical Group Industry's P/E ratio?
Joincare Pharmaceutical Group Industry's trailing twelve-month P/E ratio is 14.8x, with a price-to-book (P/B) of 1.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Joincare Pharmaceutical Group Industry?
Joincare Pharmaceutical Group Industry runs a net profit margin of 8.9%, a gross margin of 62.7%, and an operating margin of 21.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Joincare Pharmaceutical Group Industry generate?
Joincare Pharmaceutical Group Industry reported revenue of ¥15.2B for fiscal year 2025, with net income of ¥1.3B and earnings per share (EPS) of 0.73. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Joincare Pharmaceutical Group Industry pay a dividend?
Joincare Pharmaceutical Group Industry offers a trailing dividend yield of about 2.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Joincare Pharmaceutical Group Industry financially healthy?
Joincare Pharmaceutical Group Industry carries a debt-to-equity ratio of 0.33x and a current ratio of 2.37x, with a market beta of 0.20. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Joincare Pharmaceutical Group Industry a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Joincare Pharmaceutical Group Industry (600380) the key facts are: market cap ¥19.2B, P/E 14.8x, revenue ¥15.2B, 52-week range 9.08-14.21. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Joincare Pharmaceutical Group Industry's full fundamentals live
Get Joincare Pharmaceutical Group Industry's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.